Remimazolam-Based Anesthesia in Patients with Heart Failure Due to Mitral Regurgitation and Low Left Ventricular Function: A Case Series
- PMID: 38138239
- PMCID: PMC10744816
- DOI: 10.3390/medicina59122136
Remimazolam-Based Anesthesia in Patients with Heart Failure Due to Mitral Regurgitation and Low Left Ventricular Function: A Case Series
Abstract
Background and Objectives: Remimazolam is a new ultrashort-acting benzodiazepine anesthetic. Remimazolam appears to be useful in patients with severe valvular disease because of its minimal cardiovascular impact. In this retrospective case series study, we assessed the efficacy and safety of remimazolam for maintaining hemodynamic stability during anesthetic induction and maintenance. Cases: MitraClip was performed on 18 cases with severe mitral regurgitation with low left ventricular function who presented with heart failure, and remimazolam was administered for general anesthesia with induction (12 mg/kg/h) and maintenance (1 mg/kg/h). The impact of remimazolam on the hemodynamics at anesthetic induction and during anesthetic maintenance was investigated retrospectively using electronic medical records. Blood pressure decreased significantly during anesthetic induction with remimazolam (78.5 [72, 81.25] and 66.1 [62.2, 74.2], median [IQR], p = 0.0001), but only mildly, by about 10 mmHg. There was no significant change in the cardiac index (2.0 [1.8, 2.4] vs. 1.9 [1.8, 2.3], p = 0.57642) or pulse rate (73.5 ± 8.85 vs. 74.7 ± 11.7, mean ± SD, p = 0.0876) during anesthetic induction with remimazolam. All patients underwent MitraClip without major hemodynamic concerns, with no or small increases in inotropes. Conclusions: Remimazolam may be used safely in patients with severe mitral regurgitation and low left ventricular function presenting with heart failure.
Keywords: MitraClip; anesthesia; heart failure; mitral regurgitation; remimazolam.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Remimazolam Anesthesia for MitraClip Implantation in a Patient with Advanced Heart Failure.Case Rep Anesthesiol. 2021 May 5;2021:5536442. doi: 10.1155/2021/5536442. eCollection 2021. Case Rep Anesthesiol. 2021. PMID: 34035965 Free PMC article.
-
Assessing the Safety of Total Intravenous Anesthesia with Remimazolam in General Anesthesia for Transcatheter Aortic Valve Implantation of Severe Aortic Valve Stenosis: A Case Series.Medicina (Kaunas). 2022 Nov 19;58(11):1680. doi: 10.3390/medicina58111680. Medicina (Kaunas). 2022. PMID: 36422219 Free PMC article.
-
Anesthetic Management Using Remimazolam for Transcatheter Edge-to-Edge Repair of the Mitral Valve in Patients With Reduced Ejection Fraction: A Case Report of Two Cases.Cureus. 2022 Oct 26;14(10):e30706. doi: 10.7759/cureus.30706. eCollection 2022 Oct. Cureus. 2022. PMID: 36439572 Free PMC article.
-
Effects of remimazolam on hemodynamic changes during cardiac ablation for atrial fibrillation under general anesthesia: a propensity-score-matched retrospective cohort study.Can J Anaesth. 2023 Sep;70(9):1495-1503. doi: 10.1007/s12630-023-02514-2. Epub 2023 Jul 10. Can J Anaesth. 2023. PMID: 37430181 Review. English.
-
Percutaneous Mitral Valve Intervention Using MitraClip for Functional Mitral Regurgitation and Heart Failure.Int Heart J. 2021;62(1):4-8. doi: 10.1536/ihj.20-712. Int Heart J. 2021. PMID: 33518664 Review.
Cited by
-
Increased Incidence of Postoperative Nausea and Vomiting With Remimazolam Compared to Propofol Following Breast Surgery: A Single-Center, Retrospective Cohort Study.Cureus. 2025 Jun 23;17(6):e86592. doi: 10.7759/cureus.86592. eCollection 2025 Jun. Cureus. 2025. PMID: 40704269 Free PMC article.
-
Remimazolam's clinical application and safety: A signal detection analysis based on FAERS data and literature support.PLoS One. 2025 Aug 22;20(8):e0330769. doi: 10.1371/journal.pone.0330769. eCollection 2025. PLoS One. 2025. PMID: 40845004 Free PMC article.
-
Comparison of Postoperative Nausea and Vomiting Between Sedation with Remimazolam and Dexmedetomidine in Transcatheter Aortic Valve Replacement Patients: A Single-Center Retrospective Observational Study.J Clin Med. 2025 Mar 5;14(5):1759. doi: 10.3390/jcm14051759. J Clin Med. 2025. PMID: 40095883 Free PMC article.
References
-
- Hari Y., Satomi S., Murakami C., Narasaki S., Morio A., Kato T., Tsutsumi Y.M., Kakuta N., Tanaka K. Remimazolam decreased the incidence of early postoperative nausea and vomiting compared to desflurane after laparoscopic gynecological surgery. J. Anesth. 2022;36:265–269. doi: 10.1007/s00540-022-03041-y. - DOI - PubMed
-
- Borkett K.M., Riff D.S., Schwartz H.I., Winkle S.P., Panbianco D.J., Lees J.P., Wilhelm-Ogunbiyi K. A phase iia, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth. Analg. 2015;120:771–780. doi: 10.1213/ANE.0000000000000548. - DOI - PubMed
-
- Franken L.G., de Winter B.C.M., Masman A.D., van Dijk M., Baar F.P., Tibboel D., Koch B.C.P., van Gelder T., Mathot R.A.A. Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. Br. J. Clin. Pharmacol. 2018;84:320–330. doi: 10.1111/bcp.13442. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical